企業概要
Aurinia Pharmaceuticals Inc. is a biopharmaceutical enterprise dedicated to developing and delivering advanced therapies for individuals suffering from autoimmune diseases that present significant unmet medical needs in the United States and Japan markets. Operating within the healthcare sector specifically under the biotechnology industry classification, the company focuses on translating scientific innovation into accessible oral treatment options, distinguishing itself through its specialized therapeutic pipeline. As of the latest reporting period, the entity commands a market capitalization of $2.12 billion while generating trailing twelve-month revenue of $283.06 million with a workforce comprising 128 employees. These valuation and revenue figures position Aurinia as a mid-cap player with substantial market penetration, indicating that the firm has successfully established a commercial footprint despite operating in a highly competitive pharmaceutical landscape where capital efficiency and clinical success are paramount for sustaining its current scale.
財務健全性
The company reported a trailing twelve-month revenue of $283.06 million, accompanied by a net income of $287.20 million and an EBITDA of $135.71 million, highlighting a distinct structural characteristic where net income exceeds total revenue. This specific financial configuration reveals a cost structure wherein the company's reported earnings include significant non-operating income, likely derived from equity method investments or other comprehensive income sources, rather than solely from its core operational profitability. Aurinia maintains a free cash flow of $91.41 million, which provides the organization with considerable financial flexibility to fund ongoing research and development activities without immediate reliance on external equity financing. The firm's profitability metrics are exceptional, boasting a gross margin of 77.0%, an operating margin of 55.7%, and a profit margin of 101.5%, where the profit margin exceeding 100% underscores the impact of non-operating gains on the bottom line. Regarding liquidity and leverage, Aurinia holds $397.94 million in cash against total debt of $74.81 million, resulting in a conservative balance sheet profile supported by a debt-to-equity ratio of 12.87 and a robust current ratio of 5.25. The current ratio of 5.25 indicates an extremely strong short-term liquidity position, ensuring the company can comfortably meet its obligations as they come due. Furthermore, the return on equity stands at 59.9% and the return on assets is 11.2%, metrics that collectively reveal high management effectiveness in deploying shareholder capital and utilizing the company's asset base to generate substantial returns.
バリュエーション評価
Valuation metrics for Aurinia Pharmaceuticals indicate a trailing P/E ratio of 7.71 and a forward P/E of 19.11, suggesting that the market anticipates a significant expansion in earnings per share over the coming year that will nearly double the current valuation multiple. The price-to-book ratio is recorded at 3.63, which indicates that the stock is trading at a substantial premium relative to its tangible book value, reflecting investor confidence in the intangible assets and pipeline potential of the biotechnology firm. Alternative valuation measures such as the price-to-sales ratio of 7.50 and an EV/EBITDA of 13.26 provide additional context, suggesting that while the stock is priced at a premium to sales, it remains reasonably valued relative to its earnings before interest, taxes, depreciation, and amortization when compared to industry peers. The stock has exhibited volatility within a 52-week trading range bounded by a high of $16.54 and a low of $6.83, meaning the current price sits approximately 75% below the 52-week high. The beta value of 1.52 signifies that the stock price is approximately 52% more volatile than the broader market index, implying that Aurinia's share price will likely experience amplified swings during periods of market turbulence.
Growth & Income
Aurinia Pharmaceuticals demonstrates robust expansionary momentum with a year-over-year revenue growth rate of 28.8% and an extraordinary year-over-year earnings growth rate of 15073.2%, indicating that earnings are expanding at a pace vastly disproportionate to revenue due to the aforementioned non-operating income factors. As a non-dividend payer, the company does not distribute a dividend yield, maintaining a payout ratio of 0.0%, which allows management to fully reinvest generated earnings into research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is typical for biotechnology firms in the growth phase, prioritizing pipeline advancement and market share acquisition over current income generation for investors. The overall growth and income profile characterizes Aurinia as a high-growth equity where capital appreciation is driven by operational scaling and earnings accretion from external investments rather than dividend income.